Rheumatoid arthritis (RA) is a progressive autoimmune disease that causes the immune system to attack the joints, leading to swelling, stiffness, and long-term joint destruction. But it doesn’t stop at the joints—RA can affect the lungs, heart, blood vessels, and even the eyes. Left untreated, it can permanently compromise function, independence, and quality of life.
Early Action, Targeted Relief
Cohen Medical Center delivers a proactive, aggressive, and scientifically driven treatment strategy focused on preventing irreversible damage through early intervention and targeted biologic infusion therapy.
Aggressive “Treat-to-Target” Strategy at the INFUSION CENTER
Dr. Cohen’s approach to RA begins with one goal: clinical remission as early as possible. At his Infusion Center, patients are evaluated comprehensively and treated with a “treat-to-target” protocol, starting with the most appropriate and effective therapy without delay.
Rather than escalating slowly while damage accumulates, Dr. Cohen initiates early biologic infusion therapy using FDA-approved agents such as:
- REMICADE (IV infusion)
- RITUXAN (IV infusion)
- ACTEMRA (IV infusion)
- ORENCIA (IV infusion)
- SIMPONI ARIA (IV infusion)
- CIMZIA LYO (lyophilized subcutaneous injection)
These biologics are administered or managed with precision at his Infusion Center, designed specifically for autoimmune patients needing intravenous or advanced injectable therapies.
Personalized RA Biologic Plans at the INFUSION CENTER
At Cohen Medical Center, no two patients are treated the same. He tailors therapy based on disease severity, autoantibody profile, organ involvement, and lifestyle considerations. His most frequently prescribed infusion-based and injectable RA biologics include:
- REMICADE – a gold-standard TNF inhibitor delivered via IV, often used for rapid control of inflammation in moderate-to-severe RA.
- RITUXAN – targets B-cells for long-lasting effects, especially beneficial in seropositive RA or those with previous biologic failure.
- ACTEMRA – an IL-6 receptor antagonist that blocks one of the most potent inflammatory signals in RA, administered intravenously.
- ORENCIA – a unique co-stimulation blocker that modulates T-cell activation, reducing joint swelling and fatigue.
- SIMPONI ARIA – a once-monthly IV TNF blocker that offers sustained inflammation control with predictable dosing.
- CIMZIA LYO – a pegylated TNF inhibitor in lyophilized form, administered subcutaneously but monitored and initiated through the Infusion Center for safety and efficacy.
Each of these therapies is part of a customized infusion or injection program provided under close physician oversight at the Infusion Center.
INFUSION CENTER Services: Safe, Timely, and Expertly Managed Biologic Therapy
Cohen Medical Center offers:
- On-site administration of REMICADE, RITUXAN, ACTEMRA, ORENCIA, and SIMPONI ARIA
- Management and education around CIMZIA LYO for subcutaneous self-injection
- Flexible infusion scheduling
- Comfortable, physician-supervised infusion suites
- Same-week start for newly diagnosed RA patients
- Laboratory testing to guide and adjust therapy in real-time
The Infusion Center provides immediate access to medications that normally require prior authorization or hospital-based treatment delays—helping patients get ahead of their disease instead of falling behind it.
Research-Driven Innovation at the INFUSION CENTER
Dr. Cohen doesn’t just practice advanced rheumatology—he contributes to it. Through active involvement in clinical trials and infusion-based studies, he helps shape the future of autoimmune disease management. Many therapies available today—including REMICADE, RITUXAN, ACTEMRA, ORENCIA, SIMPONI ARIA, and CIMZIA LYO—have passed through clinical development programs in which Dr. Cohen participated. His Infusion Center remains at the forefront of biologic innovation, ensuring his patients benefit from the latest scientific advances the moment they’re available.
Transforming RA Outcomes Through the INFUSION CENTER
The results of this approach are extraordinary. Dr. Cohen’s RA patients often achieve:
- Rapid reduction in joint pain and morning stiffness
- Improved strength and range of motion
- Reduction or elimination of corticosteroids
- Lower disease activity scores
- Remission in patients who were previously unresponsive to therapy
These outcomes are made possible by early, aggressive care, biologic precision, and the convenience and safety of a physician-led Infusion Center model.
Cohen Medical Center: The Regional Leader in RA Infusion Therapy
With a commitment to compassionate care and clinical excellence, Cohen Medical Center continues to be a trusted choice for both patients and referring providers throughout the region. Whether you require REMICADE, RITUXAN, ACTEMRA, ORENCIA, SIMPONI ARIA infusions, or CIMZIA LYO onboarding and monitoring, you can count on our team for a safe, comfortable, and expertly managed infusion experience. Don’t wait to get the care you deserve—contact us today or schedule your consultation to learn more about how we can support your infusion therapy needs.
